Methadone detoxification using buprenorphine microinduction (Bernese method): a case report

Background

Opioid Use Disorder (OUD) requires precise pharmacological management to maintain neurobiological stability. The transition from a full agonist at the μ-opioid receptor (methadone) to a partial agonist at the μ-opioid receptor and antagonist at the κ-opioid receptor (buprenorphine) is clinically complex due to differing receptor kinetics. Traditional transition methods often necessitate opioid abstinence to avoid precipitated withdrawal (PW), which is frequently poorly tolerated by patients and can lead to treatment dropout. The Bernese Method (micro-induction) allows for a seamless cross-over by leveraging the higher receptor affinity of buprenorphine [1], enabling it to displace the full agonist gradually without triggering an acute withdrawal syndrome [2].

Methods

The aim of this case study was to evaluate the clinical safety of a micro-induction protocol for total opioid cessation. A 53-year-old male stable on methadone (15 mg/day) was admitted for voluntary inpatient detoxification to resume his career as an international heavy-vehicle driver. We implemented a 12-day cross-over protocol based on established pharmacological guidelines [1,3]. Modification of his baseline medication (gabapentin and quetiapine) was not necessary during the protocol. Buprenorphine was initiated at 0.2 mg twice daily (BID) and progressively increased while methadone was tapered. Methadone was fully discontinued on day 5. Clinical monitoring used the Objective Withdrawal Scale (OWS). Clinical data were analysed descriptively.

Results

The transition was well-tolerated. The patient achieved complete opioid discontinuation without episodes of PW, reporting only minor, self-limiting lower-limb myalgia. Descriptive clinical observation showed that OWS scores remained consistently low (scores ≤3) throughout the 12-day protocol, indicating successful neurobiological adaptation to the partial μ-opioid receptor agonist. No rescue medication was required. The patient exhibited high psychological stability and treatment adherence, driven by the specific vocational objective of returning to international freight transport. At discharge, the patient had achieved total opioid abstinence, meeting the rigorous requirements for his professional reintegration.

Conclusions

This case suggests that buprenorphine micro-induction is a safe pharmacological strategy for methadone discontinuation in chronic opioid users. By eliminating the necessity for a withdrawal period before induction, this approach prevents acute distress and enhances treatment adherence. While structured inpatient monitoring was key for success, the findings are limited by the single-case nature of the observation. This protocol should be considered as a viable first-line approach for patients with strict occupational requirements. Further prospective research is warranted to standardise these observations across diverse clinical settings to optimise long-term recovery outcomes.

DAY	BUPRENORFINE (MG/D)	METHADONE (MG/D)
1	0.2 mg BID (0.4 mg)	15
2	0.4 mg BID (0.8 mg)	15
3	0.4 mg TID (1.2 mg)	10
4	1 mg BID (2 mg)	5
5	2 mg BID (4 mg)	-
6	2 mg BID (4 mg)	-
7	1 mg TID (3 mg)	-
8	1 mg BID + 0,4 mg (2,4mg)	-
9	1 mg BID (2 mg)	-
10	0.4 mg BID (0.8 mg)	-
11	0.2 mg BID (0.4 mg)	-
12	-	-

References

1. Hämmig, R., Kemter, A., Strasser, J., Von Bardeleben, U., Gugger, B., Walter, M., Dürsteler, K.M., Vogel, M., 2016. Use of micro-doses for induction of buprenorphine treatment with marginal withdrawal symptoms. Subst. Abuse Rehabil. 7, 43-45.
2. Moe, J., O’Sullivan, F., Slaunwhite, A.K., Ghiasbeglou, H., Koh, J.J., 2020. Microdosing and standard-dosing take-home buprenorphine initiation in the emergency department: A retrospective cohort study. PLoS One 15 (3), e0230687.
3. Sorensen, J.L., Hides, L., Kay-Lambkin, F., White, J.M., 2022. The Bernese Method for buprenorphine induction: A systematic review. J. Addict. Med. 16 (4), 451-458.